These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 18790022)

  • 21. Construction and evaluation of multitracer small-animal PET probabilistic atlases for voxel-based functional mapping of the rat brain.
    Casteels C; Vermaelen P; Nuyts J; Van Der Linden A; Baekelandt V; Mortelmans L; Bormans G; Van Laere K
    J Nucl Med; 2006 Nov; 47(11):1858-66. PubMed ID: 17079820
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Nuclear medicine imaging in neurodegenerative dementias].
    Gratz S; Hahn U; Kaiser JW; Jarnig M; Schwarz J; Förstl H
    Dtsch Med Wochenschr; 2008 May; 133 Suppl 1():S5-7. PubMed ID: 18437639
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tc-99m ethylene cysteinate dimer SPECT in the differential diagnosis of parkinsonism.
    Feigin A; Antonini A; Fukuda M; De Notaris R; Benti R; Pezzoli G; Mentis MJ; Moeller JR; Eidelberg D
    Mov Disord; 2002 Nov; 17(6):1265-70. PubMed ID: 12465066
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dopamine storage capacity in caudate and putamen of patients with early Parkinson's disease: correlation with asymmetry of motor symptoms.
    Kumakura Y; Gjedde A; Danielsen EH; Christensen S; Cumming P
    J Cereb Blood Flow Metab; 2006 Mar; 26(3):358-70. PubMed ID: 16079784
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The role of positron emission tomography in the discovery and development of new drugs; as studied in laboratory animals.
    Roselt P; Meikle S; Kassiou M
    Eur J Drug Metab Pharmacokinet; 2004; 29(1):1-6. PubMed ID: 15151164
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Functional imaging in Parkinson disease.
    Nandhagopal R; McKeown MJ; Stoessl AJ
    Neurology; 2008 Apr; 70(16 Pt 2):1478-88. PubMed ID: 18413571
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A fusion PET-MRI system with a high-resolution research tomograph-PET and ultra-high field 7.0 T-MRI for the molecular-genetic imaging of the brain.
    Cho ZH; Son YD; Kim HK; Kim KN; Oh SH; Han JY; Hong IK; Kim YB
    Proteomics; 2008 Mar; 8(6):1302-23. PubMed ID: 18338828
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Molecular imaging in Alzheimer's disease.
    Lascola C
    Neuroimaging Clin N Am; 2005 Nov; 15(4):827-35, x-xi. PubMed ID: 16443493
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Imaging non motor signs in Parkinson's disease].
    Thobois S; Ballanger B; Poisson A; Broussolle E
    Rev Neurol (Paris); 2012; 168(8-9):576-84. PubMed ID: 22921250
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Single photon-emission computed tomography imaging in early Parkinson's disease.
    Antonini A; Isaias IU
    Expert Rev Neurother; 2008 Dec; 8(12):1853-64. PubMed ID: 19086881
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The utility of susceptibility-weighted imaging for differentiating Parkinsonism-predominant multiple system atrophy from Parkinson's disease: correlation with 18F-flurodeoxyglucose positron-emission tomography.
    Yoon RG; Kim SJ; Kim HS; Choi CG; Kim JS; Oh J; Chung SJ; Lee CS
    Neurosci Lett; 2015 Jan; 584():296-301. PubMed ID: 25450142
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Positron emission tomography imaging of 5-hydroxytryptamine1B receptors in Parkinson's disease.
    Varrone A; Svenningsson P; Forsberg A; Varnäs K; Tiger M; Nakao R; Halldin C; Nilsson LG; Farde L
    Neurobiol Aging; 2014 Apr; 35(4):867-75. PubMed ID: 24126162
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Improving influx constant and ratio estimation in FDOPA brain PET analysis for Parkinson's disease.
    Pan XB; Wright TG; Leong FJ; McLaughlin RA; Declerck JM; Silverman DH
    J Nucl Med; 2005 Oct; 46(10):1737-44. PubMed ID: 16204725
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Functional imaging studies of non-motoric manifestations of Parkinson's Disease.
    Stoessl AJ
    Parkinsonism Relat Disord; 2009 Dec; 15 Suppl 3():S13-6. PubMed ID: 20082973
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Label-free assay for the assessment of nonspecific binding of positron emission tomography tracer candidates.
    Assmus F; Seelig A; Gobbi L; Borroni E; Glaentzlin P; Fischer H
    Eur J Pharm Sci; 2015 Nov; 79():27-35. PubMed ID: 26341407
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Small animal PET in preclinical studies: opportunities and challenges.
    Riemann B; Schäfers KP; Schober O; Schäfers M
    Q J Nucl Med Mol Imaging; 2008 Sep; 52(3):215-21. PubMed ID: 18551093
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Resolution, sensitivity and precision with autoradiography and small animal positron emission tomography: implications for functional brain imaging in animal research.
    Schmidt KC; Smith CB
    Nucl Med Biol; 2005 Oct; 32(7):719-25. PubMed ID: 16243647
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cerebral oxygen metabolism in patients with early Parkinson's disease.
    Borghammer P; Cumming P; Østergaard K; Gjedde A; Rodell A; Bailey CJ; Vafaee MS
    J Neurol Sci; 2012 Feb; 313(1-2):123-8. PubMed ID: 21975016
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Arterial spin labelling reveals prolonged arterial arrival time in idiopathic Parkinson's disease.
    Al-Bachari S; Parkes LM; Vidyasagar R; Hanby MF; Tharaken V; Leroi I; Emsley HC
    Neuroimage Clin; 2014; 6():1-8. PubMed ID: 25379411
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A peek inside the Huntington's brain: will functional imaging take us one step closer in solving the puzzle?
    Georgiou-Karistianis N
    Exp Neurol; 2009 Nov; 220(1):5-8. PubMed ID: 19679124
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.